A clinical observation on travoprost eye drops (Travatan) reducing IOP

Objective To evaluate the efficacy and safety of travoprost reducing IOP. Methods 38 eyes of 20 primary glaucoma / ocular hypertension patients were dosed with travoprost as a single therapy / as adjunctive therapy once daily. The observed signs included IOP, visual field and complications. The follow-up duration was 12 weeks. Results Travoprost reduced IOP significantly ( P 0.01). After 12 weeks, IOP reductions ranged from 6 to 14 mmHg ,and Mean defect in visual field didn't change significantly compared with that of pre-treatment. The most complications was mild to moderate ocular hyperemia. Conclusion Travoprost reduced IOP significantly in primary glaucoma / ocular hypertension patients, and was safe and well tolerated.